R epl acement of Deficient Gene Produc t s
The introduction of genetic material (with the use of gene therapy) to compensate for a deficiency has both intuitive appeal and evident obstacles -including delivery, achievement of sustained expression, avoidance of a deleterious immunologic or tissue-based response, and potential for inducing secondary disease based on gene disruption at the DNA insertion site arising after vectors are integrated. These topics have been discussed extensively in the literature and will not be a focus of this review. Recent reports of diseases treated through the replacement of deficient gene products with overt success include severe combined immunodeficiency caused by a deficiency of adenosine deaminase 1-3 and Leber's congenital amaurosis caused by mutations in the gene encoding retinal pigment epithelium-specific protein of 65 kD (RPE65). 4 The concept of systemic delivery of a deficient enzyme to rescue cellular function in patients with lysosomal storage diseases derives from early cell-culture experiments by Neufeld and her group. 5 These investigators found that pairwise coculture of fibroblasts from patients with different forms of mucopolysaccharidosis (i.e., forms caused by mutations affecting different lysosomal enzymes) resulted in the correction of both metabolic defects on a cellular level (an event called complementation). The secreted mediators of complementation were in fact the "deficient" enzymes, each taken up by the fibroblasts with the deficiency and transported to lysosomes.
Early attempts at enzyme-replacement therapy (ERT) for lysosomal storage disorders in vivo resulted in variable and largely disappointing results. Insights came from the confluence of basic biology and, in parallel, medical inquiry. While studying a newly described type of mucolipidosis -mucolipidosis type II (also known as inclusion-cell disease) -Hickman and Neufeld 6 tried to reconcile observations made on the basis of cultures of cells obtained from patients. Multiple lysosomal hydrolases accumulated in the culture medium and, despite their abundance, did not complement other disease states. The prevailing hypothesis was that the defect was related to an enzyme that modifies multiple lysosomal hydrolases, allowing them to reenter cells. This hypothesis turned out to be true: N-acetylglucosamine-1-phosphotransferase modifies acid hydrolases through the addition of phosphomannosyl residues, which serve as "recognition" markers for both the uptake and transport of the hydrolases to lysosomes -events mediated by the mannose-6-phosphate receptor. 7 The predominant uptake pathway varies according to cell type. For example, macrophages (an important therapeutic target in Gaucher's disease) make substantial use of the mannose and asialoglycoprotein receptors.
Knowledge of the biochemistry and pathway of lysosomal enzymes resulted in clinical trials showing that ERT attenuates at least some presentations of lysosomal storage disorders, followed by approval by the Food and Drug Administration (FDA) of agents used in ERT for six lysosomal storage diseases (Table 1) .
The biologic bases of variation in the safety and efficacy of ERT are both universal and specific to the individual patient. For example, treatment involving modifications of enzymes (e.g., through the addition of mannose-6-phosphate) to target certain tissues (e.g., the heart and kidney) is ill suited to targeting others (e.g., skeletal muscle) that have inherently poor uptake potential owing to low, or no, expression of the relevant receptor. Phenotype-genotype correlations also need to be considered. Disease alleles that cause a profound paucity of enzyme expression can promote an immunologic response against ERT that limits the efficacy of the treatment. 8 Mutations with severe effect can promote the involvement of the central nervous system (as in Gaucher's disease type 2 or 3) -a difficult scenario, given the inability of current targeting strategies used in ERT to bypass the blood-brain barrier. Emerging strategies to mitigate these limitations include the use of immune tolerance regimens, 8,9 modified targeting procedures, 10, 11 or complementary therapeutic methods (e.g., those involving pharmacologic chaperones or substrate-reducing agents) (Fig. 1) .
Compensation for Functional Deficits through New Applications of FDA-Approved Drugs
The Hutchinson-Gilford progeria syndrome has an onset in childhood and is characterized by rapid progression of clinical features resembling aging, including alopecia, loss of subcutaneous fat, aggressive atherosclerosis, and degeneration of the joints, bone, and skin. 12 Patients die from vascular disease, generally before 20 years of age. The disease is caused by mutations of the LMNA gene, encoding lamin A (a structural protein of the nuclear membrane). 13 A common de novo mutation (see Glossary) results in progerin, a mutant form of pre-lamin A that harbors a deletion of 50 amino acids. Progerin is targeted to the nuclear membrane by means of a farnesyl group that is bound to its C-terminal. Subsequent cleavage of progerin by the zinc metalloproteinase ZMPSTE24 releases mature lamin A, which goes on to participate in a variety of nuclear functions. Progerin, in contrast, lacks the cleavage site and remains tethered to the nuclear membrane (Fig. 2) . On the basis of this information, attention turned to a class of drugs called farnesyl transferase inhibitors, initially developed for cancer treatment. The hope was that inhibiting the farnesylation of progerin would prevent the transport of progerin and hence its irreversible sequestration at the nuclear membrane (Fig. 2) . Nuclear blebbing (characterized by small protuberances of the nuclear membrane) is observed in cultured cells from patients with the Hutchinson-Gilford progeria syndrome. Young and his group 14 showed that, after treatment with farnesyltransferase inhibitors, cells from unaffected persons and cells from patients with the Hutchinson-Gilford progeria syndrome mislocalized prelamin A and progerin, respectively, away from the nuclear membrane, and the cells from the patients showed reduced nuclear blebbing. Treatment with farnesyltransferase inhibitors also improved growth, fat mass, and bone mineralization in mice carrying a mutation that causes the HutchinsonGilford progeria syndrome. 15 In this mouse model of the syndrome, vascular disease does not develop. Affected mice die prematurely, and the influence of farnesyltransferase inhibitors on survival was not assessed. Collins and his group 16 tested the farnesyltransferase inhibitors tipifarnib (Zarnestra) in a transgenic mouse model of the Hutchinson-Gilford progeria syndrome that has vascular disease of the aortic media; the use of tipifarnib resulted in a protective effect on disease onset and progression proportionate to the degree of inhibition of farnesylation. Taken together, these data suggest that farnesyltransferase inhibi- Wild-type protein (Panel A) folds correctly and is properly transported from the site of synthesis (e.g., the endoplasmic reticulum [ER] ) to the site of intended function (e.g., the lysosome) and performs its intended function (e.g., the catalysis of hypothetical substrate A to hypothetical metabolite B). Mutant forms of protein (Panels B and C) can fold improperly, leading to failed transport from the site of synthesis, proper transport but impaired catalytic activity, or ER-associated degradation (ERAD). All these events will result in accumulation of substrate, which could initiate events that culminate in disease. Therapeutic gain could result from the use of various types of drugs (red circles). Compensatory effects of therapy (Panel B) include the possibility that drugs (represented by drug 1) can achieve clearance of the substrate by means of alternative mechanisms (substrate-reduction therapy) and other drugs (represented by drug 2) can antagonize pathogenetic events downstream. Salvage effects of therapy (Panel C) include the possibility that any of the three types of drugs can act as pharmacologic chaperones to mediate improvement in the folding of mutant proteins, which could mitigate the phenotypic severity of disease by means of the rescue of transport (by corrector drugs [3] ), intrinsic catalytic activity (by potentiator drugs [4] ), or stability (by stabilizer drugs [5] ).
The neither alter processing of pre-lamin A nor are associated with premature features of aging, it remains unclear whether nuclear blebbing is an informative surrogate for critical phenotypes of the Hutchinson-Gilford progeria syndrome. Moreover, it is possible that more relevant pathogenic mechanisms depend on an inability of progerin to support the essential nuclear functions carried out by mature (processed) lamin A. Marfan's syndrome is a connective-tissue disorder caused by mutations in the FBN1 gene encoding the extracellular matrix protein fibrillin 1. Patients show a severe deficiency of fibrillin 1 aggregates (microfibrils) that would otherwise instruct the formation and homeostasis of elastic fibers. It was therefore hypothesized that disease manifestations (e.g., aortic aneurysm, pulmonary emphysema, eye-lens dislocation, and stretch marks on the skin) reflect a simple structural weakness of the tissues.
However, other manifestations of Marfan's syndrome -such as bone overgrowth and muscle hypoplasia -are not so easily explained. An analysis of mouse models of Marfan's syndrome has shown that microfibrils normally bind the large latent complex of the cytokine transforming growth factor β (TGF-β) and that failure of this event to occur results in increased TGF-β activation and signaling. 17 Moreover, antagonism of TGF-β signaling attenuates or prevents many disease manifestations -including aneurysm, emphysema, myxomatous degeneration of heart valves, and skeletal-muscle myopathy -in mouse models of Marfan's syndrome. 18 Previous work had shown that angiotensin II signaling increases TGF-β activity in mouse models of chronic kidney disease and that this effect can be blocked with the use of losartan, an FDAapproved antagonist of the angiotensin II type 1 receptor that is widely used to treat hypertension. Oral administration of losartan in a mouse model of Marfan's syndrome prevented aortic-root enlargement and improved aortic-wall architecture through productive remodeling. 19 Losartan also addressed manifestations outside the vascular system, including emphysema and myopathy. 18 On this basis, the Pediatric Heart Network launched a clinical trial of losartan (ClinicalTrials.gov number, NCT00429364) in patients with Marfan's syndrome. 20 Although this trial has yet to be concluded, my colleagues and I 21 treated a subgroup of children with severe and rapidly progressive Marfan's syndrome, typically leading to aortic surgery or death in early childhood, and found a reduction in the rate of aortic-root growth after the initiation of losartan therapy to approximately 10% of the rate seen in the same cohort previously (while receiving a different type of medical therapy). Both people and mice with Marfan's syndrome have elevated plasma levels of TGF-β that decrease with the use of losartan, and the level correlates with aortic size in mice. 22 These data suggest that circulating TGF-β may serve as a prognostic and therapeutic marker in patients Glossary Antisense oligonucleotides: Short, synthetic single-stranded RNA or DNA molecules that bind to target RNA and induce their degradation or inhibit their processing or translation.
De novo mutation: Any DNA sequence change that occurs during replication, such as (in the context of this article) a heritable gene alteration occurring in a family for the first time as a result of a DNA sequence change in a germ cell or fertilized egg.
Exon-intron junction:
A junction between a block of coding sequence (exon) and an adjacent block of noncoding sequence (intron) present in DNA and in precursor messenger RNA (pre-mRNA).
In-frame exon skipping: The skipping of an exon that contains a multiple of three nucleotides during splicing of premRNA, resulting in the preservation of the reading frame for translation.
Kinase: An enzyme that transfers a phosphate group to a substrate.
MicroRNA: A short regulatory form of RNA that binds to a target RNA molecule and generally suppresses its translation by ribosomes.
Nonsense-mediated mRNA decay: The process by which cells recognize and decay mRNA that encodes a premature signal for the termination of translation.
Small (or short) interfering RNA: A short, single-stranded regulatory RNA molecule that binds to and induces the degradation of target RNA molecules.
Translational readthrough: Bypass of a termination codon by the ribosome after incorporation of a random amino acid into the elongating peptide.
The New England Journal of Medicine with Marfan's syndrome, allowing for tailoring of therapeutic regimens to the individual patient. Ongoing efforts are aimed at identifying events parallel to or downstream of TGF-β signaling that could serve as therapeutic targets. For example, TGF-β can induce the activity of matrix-degrading enzymes such as matrix metalloproteinases 2 and 9. Preliminary evidence suggests that the matrixmetalloproteinase antagonist doxycycline can attenuate aortic-root growth in mouse models of Marfan's syndrome. 23, 24 TGF-β antagonism shows potential as a therapy for other genetically induced forms of aortic aneurysm. Indeed, increased aortic-wall TGF-β The LMNA gene, encoding lamin A (a structural protein of the nuclear membrane), contains 12 exons (Panel A). Normally, spliced pre-messenger RNA (mRNA) results in lamin A that encodes a recognition and cleavage site for the enzyme ZMPSTE24 (red bar) within the C-terminal globular domain (blue oval). The 1824C→T mutation in exon 11 is found in most people with Hutchinson-Gilford progeria syndrome. The mutation activates a cryptic splice donor, causing an abnormal splicing event that removes 150 nucleotides from the mRNA and hence 50 amino acids that span the ZMPSTE24 cleavage site in the C-terminal globular domain. This results in a mutant form of prelamin A (progerin) that cannot undergo C-terminal processing. As it does to lamin A, farnesyl transferase (Panel B) adds a farnesyl group to the extreme C-terminal of progerin, at a cysteine residue (indicated with the letter C) within the so-called terminal CAAX motif (with the letter A indicating an aliphatic amino acid; and X, any amino acid). The farnesyl group binds the lamin A or progerin to the membrane of the endoplasmic reticulum at the periphery of the nucleus, where ZMPSTE24 cleaves the three terminal amino acids (AAX) of both proteins; the farnesylated cysteine is then carboxymethylated (i.e., an OCH 3 group is added). Lamin A undergoes a second cleavage event by ZMPSTE24, within the C-terminal globular domain, releasing mature lamin A. Progerin remains farnesylated and tethered to the membrane, because the abnormal splicing event has deleted this cleavage site.
The New England Journal of Medicine Sm a ll Molecules a s Ther a peu tic Agent s A path to effective drug therapy for a genetic disorder that highlights both the requirements and potential of using small molecules as therapeutic agents is exemplified by the development of imatinib (Gleevec) for the treatment of chronic myelogenous leukemia. 30 Three milestones in particular marked the road to its approval by the FDA in 2001. First, an abnormally short chromosome (the so-called Philadelphia chromosome), later shown to result from a translocation between chromosomes 22 and 9, was found to be associated with chronic myelogenous leukemia. Second, the translocation was shown to result in a fusion transcript derived from the breakpoint cluster region gene (BCR) and the gene encoding the nonreceptor tyrosine kinase c-ABL (known to be homologous to the viral oncogene v-abl) and that the resultant fusion protein (BCR-ABL) had elevated and constitutive kinase activity sufficient to transform cells into leukemia. The third milestone was the implementation of small-molecule screening assays to identify compounds that specifically inhibit the activity of tyrosine kinases. These studies culminated in successful clinical trials of imatinib use in patients. This research was performed in an incremental and deliberate manner, and it resulted in a drug screening assay honed to address the central pathogenetic event of the disease (i.e., its Achilles' heel). 31 The desirable functions of small-molecule therapeutic compounds vary according to circumstances and can be subdivided into broad classes (Fig. 1) . Pharmacologic chaperones generally bind directly to mutant proteins and can counteract aspects of cellular "quality-control" systems that serve to maintain the structural precision of proteins but may be nonproductive in the context of disease. 32 Pharmacologic "correctors" and "stabilizers" can result in restored transportability and stability, respectively, and hence elevated levels of mutant proteins that retain residual function. "Potentiators" improve the inherent functional capacity of mutant proteins. The rescue of cellular or tissue function by a pharmacologic compound can also relate to direct inhibition of a toxic function (e.g., imatinib use in patients with chronic myelogenous leukemia to inhibit dysregulated kinase activity) or indirect compensation for perturbation of a critical function (e.g., clearance of toxic metabolites).
Some relevant principles of substrate reduction are illustrated through consideration of Gaucher's disease, which is caused by the tissue accumulation of glycosylceramide due to a deficiency of glucocerebrosidase activity. Limitations of ERT (particularly in treating the neuronopathic type 2 or 3 form of Gaucher's disease) have provided incentives for complementary and alternative therapies. First conceived as a means to reduce the substrate for glucocerebrosidase, 33 attention turned to the N-alkylated iminosugar N-(n-butyl)deoxynojirimycin (miglustat; previously known as NB-DNJ), an inhibitor of glycosylceramide synthase that crosses the blood-brain barrier. In clinical use, miglustat has proved effective in the management of the hematologic and bone manifestations and organomegaly of Gaucher's disease type 1 in patients in whom ERT is unsuitable. [34] [35] [36] [37] Early results regarding miglustat therapy for neuronopathic manifestations of Gaucher's disease have been less encouraging. 38 Given that glycosylceramide is also the precursor for several glycosphingolipids, miglustat is also being explored as a treatment for other diseases, including GM1 and GM2 gangliosidosis (e.g., Niemann-Pick disease and Tay-Sachs disease).
Miglustat and other iminosugar derivatives such as N-(n-nonyl)deoxynojirimycin (or NN-DNJ) and isofagomine are also pharmacologic chaperones for certain mutant forms of glucocerebrosidase. The binding of miglustat to the active site of glucocerebrosidase inhibits the activity of the enzyme at cellular pH but stabilizes the mutant protein through conformational change and, hence, avoidance of degradation pathways. Enhanced enzymatic activity can be seen at subinhibitory concentrations of miglustat or on dissociation after transport to the more acidic environment of the lysosome. This counterintuitive approach to therapy, involving the use of an active-site inhibitor to restore activity, has been applied in other contexts. 39 Other experimental strategies to treat Gaucher's disease include the use of calcium-channel blockers as molecular chaperones or proteostasis regulators to increase the concentration of the mutant enzyme that has the ability to be transported. [40] [41] [42] M a nipul ation of Gene E x pr ession -Nonsense Suppr ession
A premature signal for the termination of translation can be caused by a single nucleotide substitution that creates a premature-termination codon or the deletion or insertion of nucleotides that shifts the messenger RNA (mRNA) reading frame (i.e., a frameshift mutation) (Fig. 3) . Premature-termination codons that occur more than 50 nucleotides upstream of the final exon-intron junction generally induce transcript degradation through the nonsense-mediated mRNA decay surveillance pathway (Fig. 3) . 43 Truncated proteins that derive from any residual nonsense transcripts typically lack their intended function. In 1985, Burke and Mogg 44 showed that aminoglycoside antibiotics can suppress the effect of a nonsense mutation (an action termed "nonsense suppression") by inducing the incorporation of a random amino acid at a premature-termination codon in mammalian cells (Fig. 3) . The "stop" mutation is thus effectively ignored by the translational apparatus. Bedwell and colleagues 45, 46 later showed that aminoglycosides can increase the expression and function of the full-length cystic fibrosis transmembrane conductance regulator protein (CFTR) in cultured respiratory epithelial cells, derived from patients with cystic fibrosis, that have nonsense alleles. This phenomenon was replicated in cell lines obtained from patients with other diseases 47, 48 ; more variable results were seen in mouse models of Duchenne's muscular dystrophy 49, 50 and in patients with either Duchenne's muscular dystrophy 51, 52 or cystic fibrosis. 53, 54 A screening assay to identify new agents with potent nonsense-suppression activity resulted in the identification of PTC124 as a safe, nonaminoglycoside suppressor with oral bioavailability. 55 PTC124 was shown to increase the expression of full-length protein in mouse models of Duchenne's muscular dystrophy 56 and cystic fibrosis 57 and to improve CFTR expression and function in nasalepithelium specimens obtained from a subgroup of patients with cystic fibrosis. 58 Despite the justified excitement about a potential therapy pertinent to many genetic diseases, potential limitations also need to be considered. First, nonsense suppressors do not appear to counteract nonsense-mediated mRNA decay, greatly limiting the number of nonsense transcripts available for translation. Some studies showing efficacy in animal models have used complementary DNA-based minigenes that lack introns and thus do not properly model the molecular pathogenic event, since pre-mRNA splicing is a requirement for mammalian nonsense-mediated mRNA decay. Studies of yeast have suggested that both the inhibition of nonsense-mediated mRNA decay and nonsense suppression ("translational readthrough," or bypass of a termination codon by the ribosome after incorporation of a random amino acid) are required for the rescue of cellular function. 59 Moreover, studies of yeast suggest that transcripts that have undergone nonsense surveillance but escape degradation are not efficiently translated. 60 Second, the incorporation of any random amino acid at a premature-termination codon may not be sufficient to restore protein function, even if a full-length protein is generated, if the intended amino acid at this position (as specified by the wild-type sequence) is critical. Third, the efficiency of readthrough for all nonsense suppressors (including PTC124) is highly dependent on the nature of the "stop" codon and its broader sequence context, greatly limiting the number of nonsense alleles that can be targeted by this therapy. Fourth, readthrough of physiologic termination codons could be detrimental if it leads to the use of an alternative mechanism of transcript clearance (nonstop decay) 61 or the creation of proteins with an extended C-terminal. Finally, the apparent "readthrough" properties of PTC124 may relate, at least in part, to an artifact in the screening assay used to identify readthrough. 62 
M a nipul ation of Pr e-mR NA Splicing
Short oligonucleotides show high potential for therapeutic applications. These oligonucleotides include small interfering RNA (siRNA) and microRNA used to degrade mRNA transcripts and suppress protein translation, respectively, and antisense oligonucleotides used to manipulate splicing. Many mutant dystrophin alleles causing Duchenne's muscular dystrophy harbor nonsense or frameshift mutations that preclude protein expres- 860 sion due to nonsense-mediated mRNA decay. In contrast, many dystrophin alleles causing the more mild Becker's muscular dystrophy involve the inframe skipping of central exons, allowing for the production of dystrophin molecules that retain some residual function even though they lack a central segment. This finding suggests that induced skipping of an exon that either harbors a mutation or compensates for a frame shift should attenuate phenotypic severity. (That is, enforced skipping of such an exon might ameliorate Duchenne's muscular dystrophy so that it more closely resembles Becker's muscular dystrophy.) 
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The strategy of enforced skipping involves the uptake of antisense oligonucleotides that target splice junctions, precluding their recognition by the splicing machinery (Fig. 4) . Various modifications of antisense oligonucleotides to promote their stability, uptake, and extent to which they promote exon skipping have proved to result in the successful expression of productive proteins, both in cell culture and after local delivery to animal models [63] [64] [65] and people with Duchenne's muscular dystrophy. 66 Intravascular injection of antisense oligonucleotides has improved dystrophin expression in skeletal muscle and muscle function in mice and dogs with muscular dystrophy; the efficacy with which antisense oligonucleotides can be targeted to cardiac muscle is variable, with increased efficacy seen in association with more recent modifications to antisense oligonucleotides. 67 There are many potential limitations of this approach, including the difficulty of delivering antisense oligonucleotides, the short duration of their effect, and the diversity of mutations in the large dystrophin gene associated with Duchenne's muscular dystrophy, which may necessitate extensive optimization of the therapy for each patient. Fortunately, it seems that a limited repertoire of antisense oligonucleotides or cocktails thereof can induce compensation by means of single or multiple exon-skipping events that address the bulk Normal dystrophin pre-messenger RNA (mRNA) (only an internal segment is shown) undergoes normal splicing and results in normal dystrophin mRNA and protein (Panel A). Duchenne's muscular dystrophy (Panel B) is usually caused by premature-termination-codon mutations that either induce transcript clearance by means of nonsense-mediated mRNA decay or lead to the formation of a truncated, nonfunctional protein.
A milder form of disease, called Becker's muscular dystrophy (Panel C), is often caused by splice-site mutations that induce the skipping of an internal exon that is a multiple of three nucleotides in length during dystrophin pre-mRNA splicing. The resulting mRNA is lacking its central segment but retains an open reading frame for translation. This maintains transcript stability and allows for the production of a form of dystrophin protein that retains some residual function. The introduction of a synthetic antisense oligonucleotide (Panel D, purple bar) that binds to a splice junction of an exon containing a premature-termination codon in a patient with a typical mutation associated with Duchenne's muscular dystrophy can prevent recognition of that exon by the splicing machinery, resulting in exon skipping. By removing the premature-termination codon from the mRNA, this strategy has the proven potential to maintain stability of the mutant transcript and to allow for the production of a dystrophin protein retaining some residual function. In theory, this would result in the milder phenotype of Becker's muscular dystrophy in a patient otherwise destined to have Duchenne's muscular dystrophy. of the mutations underlying Duchenne's muscular dystrophy, according to an international database. 68, 69 Conclusions Continued efforts to develop therapies for mendelian disorders represent both an obligation and an opportunity. The obligation relates to the fact that although mendelian diseases are individually rare, they are quite common when viewed as a group, and their burden on patients is great. In addition, to a large extent, patients with rare genetic disorders have fueled progress in the fields of human genetics and molecular therapeutics through their enthusiastic participation in research, often based on a remote promise of personal gain and at a very real personal expense. The opportunity relates to the very nature of mendelian diseases; the single-gene basis of the defect underlying each mendelian disease implies genes and pathways that are sufficient to cause phenotypes of interest and are therefore inherently able to be targeted for purposes of therapeutic gain, even when the phenotype occurs in patients with a more common presentation and a more complex cause. The primary identification of genetic susceptibility loci, by means of genomewide association studies for complex traits, has provided clues to the pathogenesis of these diseases and therapies for them [70] [71] [72] and will undoubtedly continue to do so. The realization of such therapies will be facilitated, in part, by using knowledge gained from research into mendelian disorders to sort and prioritize the leads emerging from genomewide association studies.
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